帕立骨化醇不同起始剂量治疗继发性甲状旁腺功能亢进的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (30 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of different initial dose of Paricalcitol in the treatment of secondary hyperparathyroidism (SHPT).Methods A total of 80 patients with hemodialysis and SHPT who admitted to Yichun People′s Hospital of Jiangxi Province from August 2018 to August 2019 were selected as the research objects and divided into the control group,small-dose group,moderate-dose group and large-dose group according to the random number table method,with 20 cases in each group.The control group was treated with placebo,small-dose group was treated with initial dose of 0.04 μg/kg Paricalcitol,moderate-dose group was treated with initial dose of 0.08 μg/kg paricalcitol,and large-dose group was treated with initial dose of 0.1 μg/kg Paricalcitol.After 3 months of treatment,the efficacy,qualified rate of intact parathyroid hormone (iPTH) and the adverse reactions were compared among the four groups.Results After treatment,the total effective rate of moderate-dose group was higher than those of the control group,small-dose group and large-dose group,and the differences were statistically significant (P<0.05).The qualified rate of iPTH in moderate-dose group was higher than those of the control group,small-dose group and large-dose group,and the differences were statistically significant (P<0.05).There were no statistically significant differences in the incidence of adverse reactions of the small-dose group,moderate-dose group and large-dose group (P>0.05).Conclusion The moderate initial dose of Paricalcitol (0.08 μg/kg) for patients with hemodialysis and SHPT has better curative effect and higher qualified rate of iPTH,and not increase the risk of adverse reactions.

Key words： Secondary hyperparathyroidism Paricalcitol Initial dose Effectiveness Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEI Pei-dan
	JIA Chen
	CHEN Xiao XU
	Shi-zhang
	YI Jian-wei
	LUO Zi-yun
	HE Zhi-hong

Cite this article:

WEI Pei-dan,JIA Chen,CHEN Xiao XU, et al. Effect of different initial dose of Paricalcitol in the treatment of secondary hyperparathyroidism[J]. 中国当代医药, 2021, 28(4): 70-72.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I4/70

[1]	毛建萍，张倩，陈靖.慢性肾脏病患者甲状旁腺病变发生机制的研究新进展[J].中华肾脏病杂志，2019，35（8）：630-634.
[2]	付彬，郭宗琳，高祥，等.单中心维持性血液透析患者甲状旁腺激素及钙磷达标率6年的变迁[J].临床肾脏病杂志，2019，19（6）：434-437.
[3]	刁宗礼，郭维康，刘莎，等.继发性甲状旁腺功能亢进的药物治疗进展[J].中国全科医学，2015，18（26）：3245-3247，3252.
[4]	徐樱溪，赵晴，孙灿，等.活性维生素D类似物对内毒素感染小鼠肾脏细胞因子的影响[J].实用药物与临床，2017，20（3）：245-249.
[5]	刘洪萍，廖莹，李彤，等.帕立骨化醇治疗血液透析继发性甲状旁腺功能亢进症效果[J].现代中西医结合杂志，2018，28（6）：14-15.
[6]	李京，李霞，王怡.帕立骨化醇治疗血液透析患者伴继发性甲状旁腺功能亢进的疗效观察[J].中国血液净化，2019，18（6）：386-389.
[7]	郝娟，程叙扬，左力，等.帕立骨化醇不同给药方式治疗继发性甲状旁腺功能亢进症的对照研究[J].中国血液净化，2015，14（9）：540-544.
[8]	张雪琴，陆晨.帕立骨化醇在维持性血液透析患者中的应用效果分析[J].临床肾脏病杂志，2017，17（12）：761-764.
[9]	兰凯，张光伟，倪菁，等.帕立骨化醇对糖尿病肾病大鼠肾保护作用机制研究[J].西部医学，2017，29（11）：1488-1491.
[10]	刘莹，贾俊亚，林珊.腹腔注射帕立骨化醇的糖尿病肾病大鼠肾脏病理变化及自噬相关蛋白表达观察[J].山东医药，2019，59（24）：48-51.
[11]	张雪琴，庄晶，王喻，等.帕立骨化醇和骨化三醇治疗血液透析患者继发性甲状旁腺功能亢进症的疗效比较[J].中华肾脏病杂志，2018，34（10）：778-780.
[12]	王泰娜，徐斌，贾凤玉.帕立骨化醇治疗血液透析患者伴继发性甲状旁腺功能亢进[J].肾脏病与透析肾移植杂志，2015，21（1）：1-5.
[13]	李昱洁，余跃天，殷荣，等.继发性甲状旁腺功能亢进患者术后严重低钙血症的危险因素[J].临床与病理杂志，2019，39（7）：1513-1520.
[14]	戴威，孔令泉，吴凯南.甲状旁腺功能亢进症的诊断与治疗进展[J].中华内分泌外科杂志，2018，12（1）：82-84.
[15]	蔡宝乐，施辉.继发性甲状旁腺亢进对心血管系统的影响及其治疗进展[J].海南医学，2018，29（13）：1857-1860.